ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.94, indicating a potential upside of 14.77% from its current trading price of $29.57.
Notable Holdings: Key underlying holdings with significant upside potential include Glaukos Corp (53.33% upside), Darling Ingredients Inc (45.94% upside), and CCC Intelligent Solutions Holdings Inc (37.81% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with recent developments.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their implications for future stock performance.
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 125.900
Low
72.00
Averages
127.08
High
165.00
Current: 125.900
Low
72.00
Averages
127.08
High
165.00
Stifel
Buy
maintain
$115 -> $160
2026-01-22
New
Reason
Stifel
Price Target
$115 -> $160
AI Analysis
2026-01-22
New
maintain
Buy
Reason
Stifel raised the firm's price target on Glaukos to $160 from $115 and keeps a Buy rating on the shares. The firm's Epioxa survey work was better-than-anticipated, says the analyst, who revamped the firm's Epioxa sales build and arrives at 2027/2028 U.S. Epioxa sales estimates of $272M and $571M, respectively. Holding all else equal, this would drive a revenue growth acceleration from 25% year-over-year in 2026 to 46% and 45% in 2027 and 2028, respectively, the analyst tells investors.
Goldman Sachs
Buy
maintain
$112 -> $138
2026-01-09
Reason
Goldman Sachs
Price Target
$112 -> $138
2026-01-09
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Glaukos to $138 from $112 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GKOS
Unlock Now
Stephens
Overweight
maintain
$115 -> $145
2026-01-02
Reason
Stephens
Price Target
$115 -> $145
2026-01-02
maintain
Overweight
Reason
Stephens raised the firm's price target on Glaukos to $145 from $115 and keeps an Overweight rating on the shares. The firm, which slightly moderated its outlook for non-iDose U.S. glaucoma revenue, but modestly increased its iDose revenue expectations, views Glaukos as "one of the best multi-year medtech growth stories" entering 2026 as iDose is benefiting from expanding reimbursement, deeper utilization, a growing surgeon base, and a long runway of untreated and uncontrolled glaucoma patients.
UBS
Buy
maintain
$140 -> $145
2025-12-23
Reason
UBS
Price Target
$140 -> $145
2025-12-23
maintain
Buy
Reason
UBS raised the firm's price target on Glaukos to $145 from $140 and keeps a Buy rating on the shares.
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
